Test your knowledge of this quiz on the Canadian Urological Association's recommendations for genomic profiling of tumors in prostate cancer. In the era of precision medicine, genomic profiling of ...

“Without the ability to do new patient telehealth, by definition, it's really hard to impact access to care,” says Juan J. Andino, MD, MBA. In this video, Juan J. Andino, MD, MBA, considers the ...

"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD. The study that we're ...

Pluvicto was approved by Health Canada in August 2022. “This outcome is very good news for patients and their families,” said Ricardo Rendon, MD, FRCSC, President of the Canadian Urological ...

"We found that patients whose care was impacted by shortages did not have statistically significantly worse recurrence outcomes compared to patients whose care was not impacted by shortages," says ...

“It's very rare that a patient has to stay in the hospital overnight after a robotic surgery as long as they're getting a good quality operation,” says Ronney Abaza, MD, FACS. In this video, Ronney ...

From baseline to 1 year, the Ki-67 index decreased in the dietary intervention cohort by 15% and increased in the control cohort by 24%. Data from the phase 2 CAPFISH-3 trial show that a high omega-3, ...

"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh. In this video, ...

"I think that there's been a lot of positive momentum to continue coverage for telehealth without geographic restrictions, to continue coverage for phone calls, but there's still some uncertainty as ...

“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD. In this video, Jeremie Calais, MD, PhD, ...

Cretostimogene demonstrates a 74% complete response rate and extended response duration in BCG-unresponsive bladder cancer, with promising safety data. The BOND-003 trial's demographic limitations ...

The study evaluates BCG and intravesical gemcitabine in high-grade non-muscle invasive bladder cancer patients previously exposed to BCG. Preliminary results show a 94% complete response rate at six ...